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Abstract
Andrographis paniculata (Burm.f.) Nees has been widely used for centuries in Asia for the treatment of common cold
and diarrhea. Although it was previously reported to inhibit cytochrome P450 in vitro, the potential to cause herb-drug
interaction has been questioned. The purpose of this study was to evaluate the effects of A. paniculata on the pharma-
cokinetics and pharmacodynamics of midazolam, a CYP3A4 probe drug, in normal healthy volunteers. The study was an
open-label, randomized, 2-phase crossover design with a 2-weeks washout period. Twelve healthy male volunteers received
4 capsules of 250 mg A. paniculata 3 times a day orally for 7 days. Midazolam plasma concentration time profiles were
characterized after a single oral dose of 7.5 mg midazolam on the day before and after A. paniculata medication. Pharmaco-
dynamics of midazolam were also evaluated. The results demonstrated that pretreatment with A. paniculata did not change
mean pharmacokinetic parameters (Cmax, Tmax, AUC0-12, AUC0-”, T1/2, Cl/F) of oral midazolam. Since midazolam is the most
sensitive substrate for CYP3A4, thus, herb-drug interaction caused by CYP3A4 inhibition after A. paniculata in healthy
volunteers was considered not clinically relevant. However, A. paniculata potentiated the effect of midazolam in lowering
blood pressure and pulse rate. Therefore, co-administration of  A. paniculata with midazolam should be warranted.
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1. Introduction
During the past decade, the use of herbal medicines
among the general public has been increased dramatically.
Many  reports  indicated  that  herbal  medicines  were  often
taken  concurrently  with  conventional  therapy  (Lin  et  al.,
2004). Although herbal medicines are generally perceived as
safe when used alone at the recommended dose and duration,
there is increasing evidence of herb-drug interactions which
may lead to serious adverse reactions or failure of therapy
with  conventional  medicines,  such  as  bleeding  tendency
caused by ginkgo and aspirin interaction or graft rejection in
patient  taking  immunosuppressant,  cyclosporine,  with  St
John’s wort (Izzo, 2004).
Andrographis paniculata (Burm.f.) Nees (Fa-ta-lai-
jone) belongs to Family Acanthaceae. It has been widely used
for centuries in Asia to treat common cold, diarrhea, and fever
(Farnsworth and Bunyapraphatsara, 1992). The three major
active components in A. paniculata are andrographolide,
neoandrographolide and 14-deoxy-11,12-didehydro-andro-
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grapholide.  Many  studies  have  shown  that  A. paniculata
and its major components, andrographolide, have various
pharmacological activities, such as anti-inflammatory, anti-
cancer, anti-platelet aggregation, anti-viral and hepatopro-
tective effects (Mishra et al., 2007). Previous in vitro studies
demonstrated that A. paniculata extracts and andrographo-
lide inhibited activity and mRNA expression of various cyto-
chrome P450 (CYP) isozymes including CYP3A4, CYP2D6
and CYP2C in human and rat liver microsomes (Usia et al.,
2006; Pekthong et al., 2009), while CYP1A inducing activity
was also reported (Jaruchotikamol et al., 2007). These data
suggested that A. paniculata might cause herb-drug inter-
action when used in patients. However, an in vitro or even in
vivo experiment in animals cannot be precisely extrapolated
to  the clinical situation. To our knowledge, there have been
no clinical  studies relating to the interaction of A. panicu-
lata on drugs metabolized by CYP.
Midazolam is a short-acting benzodiazepine. It has
anxiolytic, sedative, hypnotic, anticonvulsant, muscle relax-
ant and amnestic effects. After oral administration of 15 mg
midazolam tablet in human, plasma concentration peaked
between 0.5-1.5 h at an average concentration of 0.05 mg/l.
The elimination half-life was 1.9 h, the mean clearance was
0.52 l/h/kg and the oral bioavailability was 49% (Langlois et
al., 1987).  Midazolam is extensively metabolized in both
the liver and the intestine via CYP3A4 and CYP3A5 to 1’-
hydroxymidazolam and 4-hydroxymidazolam, which undergo
rapid conjugation with glucuronic acid and are then excreted
into the urine within 24 h.  Many drugs and herbs have been
reported  to  cause  pharmacokinetic  drug  interaction  with
midazolam by the inhibition of CYP3A4, such as  itracona-
zole, cimetidine and grapefruit juice, which can increase the
risk of side effects such as drowsiness, confusion, memory
loss, hypotension or respiratory depression, or the induction
of CYP3A4 leading to the loss of clinical effects, such as
rifampin, nevirapine and St John’s wort (Yuan et al., 1999,
Goho, 2001, Wang et al., 2001). In the present study, we used
midazolam as a probe drug because it is the most sensitive
substrate for CYP3A and it is suggested for the study of the
relevance  of  inhibition  or  induction  by  an  investigational
drug (Huang et al., 2007).
2. Objectives
The purpose of this study was to evaluate the effects
of A. paniculata on pharmacokinetics and pharmacodyna-
mics  of  midazolam,  which  is  the  substrate  of  CYP3A4,  in
healthy volunteers.
3. Materials and Methods
3.1 Subjects
Twelve healthy male, non-smoking and non-alcoholic,
volunteers with a mean age of 27.5±6.1 years, height of
164.6±5.0 cm,  weight of 56.8±7.0 kg, and  body mass index of
20.9±1.9 kg/m
2  participated in the study. Participants were
determined  to  be  healthy  on  the  basis  of  medical  history,
physical examination, clinical chemistry, and hematologic
screening. One month before the start of the study and during
the study, all subjects were not allowed to drink alcohol or
take  any  medicines  or  herbs.  Participants  provided  their
written informed consent before participation in the study.
The  study  was  approved  by  the  ethics  committee  of  the
Faculty of Science, Prince of Songkla University (0521.1.09/
1031).
3.2 Study design
The study was an open-label, randomized, two-phase
crossover design with a 2-weeks washout period, of single-
dose (midazolam) and multiple-dose (A. paniculata) drug-
drug  interaction  study.  The  subjects  received  both  treat-
ments in random sequence. Treatment A: after an overnight
fast, volunteers received a single oral dose of 7.5 mg mida-
zolam (Dormicum
®, Hoffmann-La Roche Ltd, Basel, Switzer-
land) with 200 ml of water. Baseline pharmacokinetics of
midazolam were evaluated. Treatment B:  a midazolam phar-
macokinetic characterization was performed on day 8 of the
A. paniculata medication period with the regimen presented
as below. Both phases of midazolam pharmacokinetic study
were  conducted  identically.  Blood  samples  were  taken
through  a  venous  catheter  before  administration  of  mida-
zolam (T0) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 h
post dose. The heparinized plasma was collected and stored
at -20°C until analysis.
3.3 A. paniculata medication
Each  volunteer  received  4  capsules  of  250  mg  A.
paniculata  t.i.d. orally for 7 days and 4 capsules once in the
morning on day 8, 1 hour before midazolam administration.
A. paniculata  capsules (Lot no. CAP030) were manufactured
by the Department of Pharmacognosy and Pharmaceutical
Botany,  Faculty  of  Pharmaceutical  Sciences,  Prince  of
Songkla University, Thailand. Analysis of the A. paniculata
main  constituent  (andrographolide)  in  the  capsules  was
performed as described previously
 (Jain et al., 2000). The
content of andrographolide per capsule was 8.36±0.06 mg.
3.4 Midazolam analysis
Midazolam concentration in plasma was determined
by HPLC method (Lehmann and Boulieu, 1995). The 500 µl of
sample was added with 1 ml of diethyl ether. The mixture was
vortexed for 5 minutes and centrifuged at 1,000×g for 10 min-
utes. The 800 µl of upper organic phase was separated and
evaporated at 35°C under air flow. The residue was reconsti-
tuted in 100 µl of the mobile phase and 50 µl was injected
into  the  HPLC  system  (Agilent  Technologies)  using  C8535 M. Wongnawa et al. / Songklanakarin J. Sci. Technol. 34 (5), 533-539, 2012
reversed-phase column (Phenomenex Inc, USA). The mobile
phase  consisted  of  0.05M  KH2PO4  (pH  4.0):  acetonitrile:
methanol (55:30:15 v/v/v), at a flow rate of 1.2 ml.min
-1. The
peak was detected using a UV detector set at 210 nm. The
standard midazolam was eluted at around 11 min (Figure 1,
2). The assay was validated according to the guideline (US.
FDA. 2001) with the LLOQ of 4.64 ng/ml, recoveries of 88-
98%,  inter-/intraday  CV  and  accuracy  of  1.66/2.54%  and
100.27-99.46 %, respectively.
3.5 Andrographolide analysis
Andrographolide concentration in plasma samples
from  all  subjects  at  1  h  after  oral  administration  of  the  last
dose of A. paniculata was determined as described pre-
viously (Suo et al., 2007) with some modifications.  The 500
µl of sample and internal standard 50 µl (carbamazepine in
methanol, 5 µg/ml), were added with 1.2 ml of chloroform.
The mixture was vortexed for 15 minutes and centrifuged at
1,000×g for 10 minutes. The 1000 µl of organic phase was
separated and evaporated at 40°C
 under air flow. The residue
was reconstituted in 100 µl of the mobile phase and 30 µl was
injected into the HPLC system (Agilent Technologies) using
C18 reversed-phase column (Eclipse XDB). The mobile phase
consisted of methanol: water (52:48 v/v), at a flow rate of 0.8
ml/min. The peak was detected using a UV detector set at
225 nm. The standard andrographolide and internal standard
were eluted at around 6 and 8 min, respectively (Figure 3).
The assay was validated according to the guideline (US. FDA.
2001)  with  recoveries  of  76-111%,  LLOQ  of  24.29  ng/ml,
inter-/intraday CV and accuracy of 2.31/3.76 % and 105.91-
107.7 %, respectively.
3.6 Subject monitoring
After drug administration, vital signs (blood pressure,
pulse rate, respiration rate and body temperature) were moni-
tored at 1, 1.5, 2, 4, 8 and 12 h. Subjects were asked for un-
usual symptoms periodically.
3.7 Meausurement of pharmacodynamics of midazolam
The pharmacodynamics of midazolam were estimated
predosing and at  0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10 and 12 h
post dose. The alertness score (Langlois et al., 1987) was
chosen as the pharmacodynamic index, using the score: 4 =
alert, 3 = drowsy, 2 = ataxia+dysarthria, 1 = asleep (rousable by
voice), and 0 = asleep (not rousable by voice).
3.8 Pharmacokinetics analysis
Pharmacokinetic parameters (Cmax, AUC0-t, AUC0-”,
Tmax,  T1/2,  and  Cl/F)  of  midazolam  were  analyzed  by  non-
compartment model with the use of WinNonlin professional
Software Version 1.1 (Pharsight, Mountain View, CA).
Figure 1. Chromatogram of (A) blank plasma, (B) blank plasma
spiked with standard midazolam (150 ng/mL).
Figure 2. Chromatogram  of  (A)  plasma  obtained  from  a  subject
before treatment with midazolam, (B) plasma obtained
from a subject receiving a single oral dose of 7.5 mg
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3.9 Statistical analysis
The results were presented as the mean±standard
deviation  (X ±SD).  All  data  were  analyzed  by  one-way
ANOVA followed by LSD or paired t-test, except for the alert-
ness scores, which were analyzed by Wilcoxon signed-rank
test. A difference was considered significant at p<0.05. The
software used was the SPSS (Version 11.5, SPSS Inc, Chicago,
IL, USA.).
4. Results
4.1 Midazolam pharmacokinetic study
Mean plasma concentration-time profiles of mida-
zolam  before  and  after  treatment  with  A. paniculata  are
shown in Figure 4. The mean Cmax, Tmax, AUC0-12h , AUC0-”,
T1/2 and Cl/F of midazolam were not changed significantly
(p>0.05), as shown in Table 1.
4.2 Midazolam pharmacodynamic study
The mean arterial pressure, pulse rate, respiration rate
and  body  temperature  are  shown  in  Table  2.  In  subjects
receiving oral 7.5 mg midazolam after A. paniculata (Treat-
ment B), the mean arterial pressure and pulse rate were signi-
ficantly decreased when compared with midazolam alone
(Treatment A) at 2 h and 1 h post-dose, respectively (p<0.05),
while the mean respiration rate and body temperature were
not changed. The mean alertness score was slightly decreased
Figure 3. Chromatogram of (A) blank plasma, (B) blank plasma
spiked with standard andrographolide (300 ng/mL) and
carbamazepine (internal standard, 5 µg/mL), (C) plasma
obtained from a subject at 1 h. after oral administration
of  4 capsules of 250 mg A. paniculata.
Figure 4. Mean plasma concentration time-profiles of midazolam
after a single oral dose of 7.5 mg midazolam before (base-
line,  ) and after pretreatment with 4 capsules of 250
mg  A. paniculata  t.i.d. orally  for 7 days  ( ).
Table 1. Pharmacokinetic parameters (X± SD) of midazolam
in 12 subjects receiving a single oral dose of 7.5 mg
midazolam (phase 1) compared with after pretreat-
ment with 4 capsules of 250 mg  A. paniculata  t.i.d.
orally  for 7 days (phase 2)
     Parameters Phase 1 Phase 2 p-value
Cmax (ng/ml)     94.76±55.28     74.78±52.02 0.132
AUC0-12 (ng.h/ml) 151.58±65.66 163.14±92.68 0.445
0- AUC (ng.h/ml) 181.24±68.51    194.47±101.07 0.476
Tmax (h) 0.583±0.19 0.583±0.22 1.000
T1/2 (h)    2.05±0.63    2.09±0.60 0.808
Cl/F (l/h/kg) 0.047±0.02 0.046±0.02 0.638537 M. Wongnawa et al. / Songklanakarin J. Sci. Technol. 34 (5), 533-539, 2012
Table 2. The pharmacodynamic parameters of 12 subjects
receiving a single oral dose of 7.5 mg midazolam
(phase 1) compared with after pretreatment with 4
capsules of 250 mg  A. paniculata  t.i.d. orally  for
7 days  (phase 2)
Mean arterial pressure (mmHg) (X ± SD)
Time (h)
Phase 1 Phase 2 p-value
0 89.78±10.84 89.56±7.42 0.904
1 85.37±9.43 76.13±8.55
** 0.058
1.5 84.78±6.57 77.92±10.19
** 0.051
2 85.36±7.80 76.69±7.04
**   0.014
 a
4 82.67±5.03
* 80.11±6.91
** 0.383
8 83.06±5.88 78.97±3.99 0.098
12 87.14±7.66 85.75±7.70 0.645
Pulse rate (beats/min) (X ± SD)
Time (h)
Phase 1 Phase 2 p-value
0 65.33±10.46 66.92±6.01 0.566
1 61.70±5.48 59.00±5.16
** 0.012
a
1.5 59.00±10.39 58.92±7.55
** 0.972
2 56.83±5.70
* 59.08±7.74
** 0.409
4 66.17±8.82 64.17±6.73 0.425
8 62.75±7.77 62.92±8.87 0.956
12 65.67±6.71 68.25±7.48 0.251
Respiration rate (breaths/min) (X± SD)
Time (h)
Phase 1 Phase 2 p-value
0 18.33±2.39 17.67±2.06 0.560
1 17.60±1.58 18.20±0.63 0.273
1.5 17.40±1.35 18.00±0.94 0.343
2 17.67±1.44 18.00±0.85 0.551
4 19.17±1.03 18.50±1.24 0.266
8 18.50±0.90 18.00±0.85 0.191
12 18.83±1.03 18.50±1.24 0.586
Body temperature (°C) (X± SD)
Time (h)
Phase 1 Phase 2 p-value
0 36.24±0.45 36.38±0.35 0.421
1 36.42±0.34 36.65±0.11 0.065
1.5 36.45±0.35 36.67±0.13 0.118
2 36.54±0.31 36.68±0.08 0.160
4 36.65±0.25 36.70±0.07 0.541
8 36.64±0.21 36.68±0.11 0.586
12 36.67±0.16 36.68±0.09 0.874
* Significantly different from T= 0 h of phase 1 at  p<0.05
**Significantly different from T= 0 h of phase 2 at  p<0.05
a Significantly different when compared between phase 1
and phase 2 at  p<0.05
4.3 The concentration of andrographolide in plasma
Andrographolide  could  not  be  detected  in  plasma
samples from any subject at 1 h after oral administration of
the last dose of  A. paniculata with the LLOQ of 24.29 ng/ml.
5. Discussion
A. paniculata is one of the most well known herbal
medicines in Thailand for relief of sore throat (Satyapan et
al., 2010). It has been placed in the National List of Essential
Medicines  for  treatment  of  non-infectious  diarrhea  and
common cold since 1999
 (National Drug Committee, 2011).
Although it is a herbal medicine developed from a single plant
with  the  evidence  indicating  its  safety  for  use  in  humans,
according to the criteria of The National Drug Committee, data
concerning interaction of A. paniculata with other medicines
used in conventional therapy has never been reported. In the
present study, we demonstrated that pretreatment with 4 cap-
sules of 250 mg A. paniculata t.i.d. for 7 days in 12 normal
volunteers did not significantly change the mean pharma-
cokinetic parameters (Cmax, Tmax, AUC0-12h,  0- AUC ,   T T1/2, Cl/F)
of oral midazolam. Each capsule of A. paniculata used in the
study contained about 8.36±0.06 mg of andrographolide.
The dosage regimen of A. paniculata used in this study cor-
responds  to  about  1.8  mg/kg/day  of  the  active  principle
andrographolide (12 capsules of 8.36 mg of andrographolide
per day and average weight of the subjects was 56.8 kg) and
is  close  to  that  recommended  for  treatment  of  respiratory
diseases (4 capsules of 250 mg q.i.d. orally for 7 days)
 (Na-
tional Drug Committee, 2011).  Since we realized that andro-
grapholide has a short half-life (3.9 h.) (Panossian et al.,
2000), another 4 capsules of A. paniculata  were given to the
subjects 1 h before midazolam administration after 7 days of
Table 3. The mean alertness scores of 12 subjects receiving
a single oral dose of 7.5 mg midazolam (phase 1)
compared with after pretreatment with 4 capsules of
250 mg  A. paniculata  t.i.d. orally  for 7 days  (phase
2)
Alertness score (X ± SD)
Time (h)
Phase 1 Phase 2 p-value
0.25 3.67±0.49 3.42±1.00 0.317
0.5 2.58±1.31 2.08±1.16 0.319
0.75 1.75±1.29 1.00±1.04 0.107
1 1.75±1.29 1.00±1.04 0.142
1.5 1.67±1.44 1.25±0.87 0.339
2 1.92±1.56 1.58±1.31 0.490
4 2.92±1.44 3.58±0.90 0.131
6 3.50±0.90 3.83±0.39 0.102
Alertness scores: 0 = unrousable to voice, 1 = rousable to
voice, 2 = ataxia+dysarthria,  3 = drowsy, 4 = alert
(1.75 VS 1.00, at 0.75-1 h post dose) but was not significantly
different (p>0.05) (Table 3). No other adverse effects were
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A. paniculata medication, in order to assure the inhibitory
effect of  A. paniculata and to determine the plasma concen-
tration of andrographolide. However, it is interesting to note
that  plasma  level  of  andrographolide  was  negligible  (less
than the LLOQ of 24.29 ng/ml). This might be because of the
poor  oral  bioavailability  (2.67%)  of  andrographolide  as
reported by Xu et al. (2009) and Wangboonskul et al. (2006).
On the contrary, according to Panossian et al.
 (2000), using
Kan-Jang tablets which contained the extracts of A. pani-
culata and A. senticosus,  the calculated steady state plasma
concentration of andrographolide for multiple doses of A.
paniculata after the normal therapeutic dose regimen (3x4
tablets of Kan Jang/day, about 1 mg andrographolide/kg/day)
was approximately 1.9 µM (660 ng/ml), which is, however,
less than the concentration affecting CYP activities in vitro
(12.5-50  µM),  as  reported  previously
  (Usia  et  al.,  2006;
Pekthong et al., 2009; Jaruchotikamol et al., 2007).  This could
be the explanation of no clinical effect of A. paniculata on
pharmacokinetics of midazolam in our study. Oral midazolam
was used as a CYP3A probe drug since it is the most sensi-
tive substrate for both intestinal and hepatic CYP3A (Chung
et al., 2006). Regulatory authorities suggest that in case of a
negative drug interaction with the most sensitive substrate,
it can be presumed that less sensitive substrates would also
be unaffected
 (Huang et al., 2007).  Thus, it is indicated that
pharmacokinetic drug interaction between A. paniculata and
CYP3A4 substrate is clinically insignificant.
We also monitored the effect of A. paniculata on the
pharmacodynamics of midazolam. It was demonstrated that A.
paniculata when coadministered with midazolam decreased
mean arterial pressure and pulse rate, whereas the respiratory
rate and body temperature were not changed when compared
with a single oral 7.5 mg midazolam alone. Although the side
effect of A. paniculata on cardiovascular system or central
nervous system in human is rarely reported. A. paniculata
has been reported to decrease blood pressure and pulse rate
in  rat  (Huang,  1987;  Zhang  and  Tan,  1997;  Yoopan  et  al.,
2007). Thus, it is possible that A. paniculata has an additive/
synergistic  effect  on  blood  pressure  and  pulse  rate  with
midazolam. Moreover, A. paniculata has been reported to
potentiate the hypnotic effect of pentobarbitone in rat, which
indicates that it may act at the barbiturate receptors in the
brain  (Mandal  et  al.,  2001).  A. paniculata  also  produced
hypothermia, and exhibited motor incoordination and muscle
relaxant activity (Mandal et al., 2001). According to the above
data, it is suggested  that A. paniculata extract has CNS-
depressant action. In our study, the mean alertness score in
the subjects who received midazolam after A. paniculata was
slightly lower than after midazolam alone but the difference
was not statistically significant. It is noted that the dose of
midazolam used in this study was 7.5 mg which is the mini-
mum therapeutic dose. It is possible that at the maximum
therapeutic dose of 15 mg midazolam, the additive effect of
A. paniculata on CNS depression might be more obvious
which may lead to serious side effects.
6. Study limitation
In  the  present  study,  the  method  of  midazolam
analysis had no internal standard since we could not find a
suitable  one.  However,  we  could  get  good  results  in  the
method validation which are in the acceptable range accord-
ing to the US FDA guideline.
7. Further study
An  ongoing  project  is  studying  the  interaction
between A. paniculata and other herbs which increase the
absorption of andrographolide and the correlation with CYP
inhibition in vivo.
8. Conclusion
No significant changes in pharmacokinetics of oral
midazolam were demonstrated after medication with  A.
paniculata at the recommended dosage regimen for the treat-
ment of respiratory tract infection. It is indicated that there is
no clinically relevant CYP3A4 inhibition after A. paniculata
treatment in healthy volunteers. Thus, pharmacokinetic inter-
action between A. paniculata and CYP3A4 substrates is
considered clinically insignificant. However, A. paniculata
affected the pharmacodynamics of oral midazolam. There-
fore,  the  risk  associated  with  the  additive  or  potentiative
effects of A. paniculata and CNS depressants (e.g., alcohol,
barbiturates, benzodiazepines) should be warranted.
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